Skip to Content

AADAC Antibodies

AADAC Antibodies

AADAC antibodies are developed to target the enzyme Arylacetamide Deacetylase (AADAC), which is primarily involved in drug metabolism and lipid processing. AADAC is an important serine hydrolase enzyme found in the liver and small intestine, where it contributes to the hydrolysis of various xenobiotics, drugs, and endogenous compounds.

Content

AADAC plays a key role in the biotransformation of drugs and other chemical compounds. It catalyzes the hydrolysis of ester and amide bonds, converting arylacetamides and related compounds into their respective metabolites. AADAC is particularly important for the metabolism of drugs such as lidocaine, rifampicin, and certain opioid analgesics. Beyond drug metabolism, AADAC also participates in lipid metabolism by hydrolyzing monoacylglycerols and other lipid substrates.

Application

AADAC antibodies are used in various research applications, including:

  • Immunohistochemistry (IHC): Employed to localize AADAC within tissue sections, providing insights into its distribution, particularly in the liver and gastrointestinal tract. IHC with AADAC antibodies is useful for studying its role in drug metabolism and identifying how its expression may be altered in conditions like liver cirrhosis or drug-induced liver injury.
  • Immunofluorescence (IF): Allows for the detailed visualization of AADAC at the cellular level, showing its localization within cells, particularly hepatocytes and enterocytes. IF is essential for understanding how AADAC interacts with other metabolic enzymes and how its cellular distribution may change in response to different stimuli.
  • Enzyme-Linked Immunosorbent Assay (ELISA): Utilized for quantifying AADAC levels in biological samples, facilitating research into how variations in enzyme expression affect drug metabolism. ELISA assays can be used in pharmacokinetic studies to better understand how AADAC influences drug clearance and bioavailability.

These applications make AADAC antibodies critical tools for advancing research in pharmacology, toxicology, and liver function. They allow scientists to study how AADAC contributes to the metabolism of various drugs, understand individual variability in drug responses, and explore the potential of AADAC as a target for modifying drug metabolism to improve therapeutic outcomes.

AffiAB® Anti-AADACL2 Rabbit pAb

CAT# AFG-BSV-0042
Size: 100 μL
350.00

AffiAB® Anti-AADACL1 Rabbit pAb

CAT# AFG-BSV-0041
Size: 100 μL
350.00

AffiAB® Anti-AADAC/DAC Rabbit pAb

CAT# AFG-BSV-0040
Size: 100 μL
350.00

AffiAB® AADACL1 Antibody

CAT# AFG-FNB-000037
Size: 100 μL
452.00

AffiAB® Anti-AADAC Antibody

CAT# AFG-BMG-1754
Size: 100 µl
193.08

AffiAB® Anti-AADACL4 Antibody

CAT# AFG-BMG-1691
Size: 100 µl
193.08

AffiAB® Anti-AADACL3 Antibody

CAT# AFG-BMG-1684
Size: 100 µl
193.08
815.00

AffiAB® Rabbit anti-AADAC Antibody

CAT# AFG-DDA-1467
Size: 100 μL
274.55

AffiAB® AADACL4 Polyclonal Antibody

CAT# AFG-PAB-00012
Size: 100 µL
Conjugation: Unconjugated
533.50

AffiAB® AADACL2 Polyclonal Antibody

CAT# AFG-PAB-00011
Size: 100 µL
Conjugation: Unconjugated
533.50

AffiAB® AADAC Polyclonal Antibody

CAT# AFG-PAB-00010
Size: 100 µL
Conjugation: Unconjugated
533.50

AffiAB® Rabbit anti-AADAC Antibody

CAT# AFG-YBP-0237
Size: 100 µL
457.00

AffiAB® AADACL4 Antibody

CAT# AFG-IVA-00099
Size: 25 µL
Terminal: Middle region
378.95

AffiAB® AADACL3 Antibody

CAT# AFG-IVA-00098
Size: 25 µL
Terminal: C-terminal region
378.95

AffiAB® Aadacl1 Antibody

CAT# AFG-IVA-00096
Size: 25 µL
Terminal: Middle region
378.95

AffiAB® AADACL2 Antibody

CAT# AFG-IVA-00097
Size: 100 µg
Terminal: N/A
705.65

AffiAB® AADAC Antibody

CAT# AFG-IVA-00095
Size: 100 µg
Terminal: N/A
705.65